(Q53154556)

English

Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.

scientific article published on 27 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

adaptive radiation therapy

0 references

phase II clinical trial

0 references

object named as

Minesh P Mehta

16

0 references

Maria Werner-Wasik

12

object named as

Maria Werner-Wasik

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Laurie E. Gaspar

13

object named as

Laurie E Gaspar

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

author name string

Derek R McHaffie

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Pierre Chabot

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Anne Dagnault

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

John H Suh

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Marie-Andrée Fortin

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Eric Chang

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Robert Timmerman

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Luis Souhami

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

John Grecula

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Abdenour Nabid

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Chris Schultz

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

David Brachman

14

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Tarak Mody

15

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

publication date

27 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

105

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

301-308

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

https://scigraph.springernature.com/pub.10.1007/s11060-011-0590-9

0 references

Intracranial metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Stereotactic radiosurgery for four or more intracranial metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0590-9

21 January 2018

MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

METASTATIC BRAIN TUMORS. RESULTS OF SURGICAL AND NONSURGICAL TREATMENT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-011-0590-9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21523486

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53154556&oldid=1872276565"